DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical, biotechnology
and medical device industries, today announced that Mr. Thomas Lynch,
non-executive chairman of the board of directors, has notified ICON that
he will retire as chairman on 31 March 2016 and will not stand for
re-election to the board at the company's annual general meeting in July
2016. Mr. Lynch has been a non-executive director of ICON since 1994 and
served as senior independent director from 2010 to 2012 and as chairman
since January 2013.
Mr. Lynch commented "Having served as chairman since January 2013, I
believe the timing is right for me to relinquish the chair so that I can
focus more on other responsibilities and opportunities outside of ICON.
In addition, as my current term as a director will expire at the
company's annual general meeting in July 2016, I have decided not to
stand for a further term and will retire from the board at the annual
general meeting. I retire from the ICON board after twenty two
years in July next with great satisfaction with ICON's growth and
success over that period and am proud of its emergence as a global
industry leading clinical research organisation. It has been a privilege
to have worked with the ICON leadership teams over those years. I wish
ICON every success in the future."
On behalf of the board, ICON's chief executive officer, Mr. Ciaran
Murray, commented "Thomas has made a significant contribution to the
ICON board in his 22 years as a non-executive director. His deep
knowledge of the pharmaceutical industry has been a valuable asset to
the board during his long and distinguished board service. The ICON
board wishes him all the best with his future endeavours."
ICON's senior independent director, Mr. Declan McKeon, will serve as
acting chairman from Mr. Lynch's retirement as chairman and the board
will initiate a process to appoint a new chairman.
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 90 locations in 37 countries and
has approximately 11,900 employees. Further information is available at www.iconplc.com.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20160329005633/en/
ICON plc
Investor Relations, 1-888-381-7923
or
Brendan
Brennan, + 353 -1-291-2000
Chief Financial Officer
or
Simon
Holmes, + 353 -1-291-2000
EVP Investor Relations and Corporate
Development
Source: ICON plc
News Provided by Acquire Media
